Systemic Lupus Erythematosus – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Systemic Lupus Erythematosus – Pipeline Review, H1 2020’, provides an overview of the Systemic Lupus Erythematosus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus

– The report reviews pipeline therapeutics for Systemic Lupus Erythematosus by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Systemic Lupus Erythematosus therapeutics and enlists all their major and minor projects

– The report assesses Systemic Lupus Erythematosus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

ACEA Therapeutics Inc

Akeso Inc

Alpine Immune Sciences Inc

Aluda Pharmaceuticals Inc

Amgen Inc

Apellis Pharmaceuticals Inc

Apimeds Inc

APT Therapeutics Inc

Asahi Kasei Pharma Corp

Astellas Pharma Inc

AstraZeneca Plc

Atlantic Bio Sci LLC

Aurinia Pharmaceuticals Inc

BellBrook Labs LLC

Bio-Path Holdings Inc

BioAegis Therapeutics Inc

Biocon Ltd

Biogen Inc

Biotest AG

Boehringer Ingelheim International GmbH

Boston Pharmaceuticals Inc

Bristol-Myers Squibb Co

Capricor Therapeutics Inc

Carna Biosciences Inc

Cells for Cells SA

Chipscreen Biosciences Ltd

Chong Kun Dang Pharmaceutical Corp

Citryll BV

Corbus Pharmaceuticals Inc

Corestem Inc

CuraVac Inc

Cyteir Therapeutics Inc

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Domainex Ltd

Eli Lilly and Co

Epsilon-3 Bio Ltd

Ergon Pharmaceuticals LLC

Exinda Therapeutics LLC

F. Hoffmann-La Roche Ltd

Galapagos NV

Genentech Inc

GeneScience Pharmaceuticals Co Ltd

Genesen Co Ltd

Genosco Inc

Genovax Srl

Gilead Sciences Inc

GlaxoSmithKline Plc

Good T Cells Inc

HanAll Biopharma Co Ltd

Hanmi Pharmaceuticals Co Ltd

HemoGenyx LLC

Ichnos Sciences Inc

Idorsia Pharmaceutical Ltd

IL-2Rx Inc

Iltoo Pharma

Immplacate

Immune Modulation Inc

Immungenetics AG

ImmunoQure AG

Immunwork Inc

Immupharma Plc

InnoCare Pharma Ltd

Innovimmune Biotherapeutics Inc

iSD Immunotech ApS

Janus Biotherapeutics Inc

JiangSu Qyuns Therapeutics Co Ltd

Johnson & Johnson

Jura Bio Inc

K-Stemcell Co Ltd

Kangpu Biopharmaceuticals Ltd

Karyopharm Therapeutics Inc

Kezar Life Sciences Inc

Kine Sciences

Kiniksa Pharmaceuticals Ltd

Kyowa Kirin Co Ltd

Lead Discovery Center GmbH

MedAnnex Ltd

MENTRIK Biotech LLC

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

MorphoSys AG

Mount Tam Biotechnologies Inc

Nektar Therapeutics

Neovacs SA

Novartis AG

Octagon Therapeutics Inc

Omeros Corp

Pfizer Inc

Pharchoice Therapeutics Inc

ProNoxis AB

Provention Bio Inc

Ra Pharmaceuticals Inc

ReAlta Life Sciences Inc

RedHill Biopharma Ltd

Regen BioPharma Inc

RemeGen Ltd

Resolve Therapeutics LLC

Rheos Medicines Inc

Sanofi

Sareum Holdings Plc

SBI Biotech Co Ltd

Sengenics International Pte Ltd

Shanghai GeneChem Co Ltd

Shanghai Junshi Bioscience Co Ltd

SinoMab Bioscience Ltd

StingInn LLC

Suzhou Sinovent Pharmaceuticals Co Ltd

SynAct Pharma AB

Taiho Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd

TherapyX Inc

Tonix Pharmaceuticals Holding Corp

UCB SA

Viela Bio Inc

Visterra Inc

Voronoi

Xencor Inc

XTL Biopharmaceuticals Ltd

ZyVersa Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Systemic Lupus Erythematosus - Overview

Systemic Lupus Erythematosus - Therapeutics Development

Systemic Lupus Erythematosus - Therapeutics Assessment

Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development

Systemic Lupus Erythematosus - Drug Profiles

Systemic Lupus Erythematosus - Dormant Projects

Systemic Lupus Erythematosus - Discontinued Products

Systemic Lupus Erythematosus - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Systemic Lupus Erythematosus, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Systemic Lupus Erythematosus – Pipeline by AbbVie Inc, H1 2020

Systemic Lupus Erythematosus – Pipeline by ACEA Therapeutics Inc, H1 2020

Systemic Lupus Erythematosus – Pipeline by Akeso Inc, H1 2020

Systemic Lupus Erythematosus – Dormant Projects, H1 2020

Systemic Lupus Erythematosus – Discontinued Products, H1 2020

Systemic Lupus Erythematosus – Discontinued Products, H1 2020 (Contd..1), H1 2020

List of Figures

List of Figures

Number of Products under Development for Systemic Lupus Erythematosus, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports